- Home
- IBTA vs AVTX Comparison
IBTA vs AVTX Comparison
Compare IBTA & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBTA | AVTX |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | 33 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 830.3M | 801.8M |
| IPO Year | 2024 | 2015 |
Fundamental Metrics
Financial Performance| Metric | IBTA | AVTX |
|---|---|---|
| Price | $39.92 | $14.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | $36.14 | ★ $44.08 |
| AVG Volume (30 Days) | 167.2K | ★ 926.6K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $342,389,000.00 | $27,813,137.00 |
| Revenue This Year | $3.20 | N/A |
| Revenue Next Year | $8.88 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $19.10 | $12.51 |
| 52 Week High | $43.43 | $24.27 |
Technical Indicators
Market Signals| Indicator | IBTA | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.53 | 37.58 |
| Support Level | $35.30 | $15.11 |
| Resistance Level | $40.02 | $20.54 |
| Average True Range (ATR) | 1.64 | 0.82 |
| MACD | -0.47 | -0.06 |
| Stochastic Oscillator | 23.57 | 32.95 |
Price Performance
Historical ComparisonAbout IBTA Ibotta Inc.
Ibotta Inc operates a digital promotions platform, the Ibotta Performance Network (IPN), which connects consumer packaged goods (CPG) brands with consumers through a network of publishers. It sources digital offers from clients and distributes them via its technology platform, earning revenue when promotions result in consumer transactions. The platform supports offers across grocery and general merchandise categories, including toys, clothing, beauty, electronics, pet, and home products. The majority of its revenues is derived from the fees charged to clients when consumers redeem offers on the IPN by purchasing promoted products.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.